There are 2 factors that now limit access to Turing Pharmaceutical’s Daraprim, a major and often-preferred component of treatment for toxoplasmosis: 1) its (at...
Read More
If you’re breathing air, you’re very likely to know that, in August, Turing Pharmaceuticals increased the list price of its newly purchased brand-name...
Read More
My review of Atul Gawande’s Being Mortal: Medicine and What Matters in the End is available in the latest issue of the Journal of the American Medical...
Read More
The annual costs of disease-modifying therapies (DMTs) for multiple sclerosis (MS) have increased at ridiculous rates over the last 2 decades, according to a new study...
Read MoreGabrielle Strobel‘s comprehensive coverage of the phase 1 study of Biogen’s aducanumab, its presentation in Nice, France, and the ensuing hullabaloo can be...
Read More
Citron Research, a stock-commentary website, has dropped a (another) bomb on Questcor Pharmaceuticals (QCOR). According to Citron’s latest research, QCOR’s...
Read More